Protein Therapeutics Targeted at the TNF Superfamily

Advances in Pharmacology

Volumn 66, Issue , 2013, Pages 51-80

  Ware, Carl F ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Antibody biologic; Autoimmune disease; Inflammation; Lymphotoxin; Receptor decoy; TNF antagonist

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; MICRORNA; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; IMMUNE SYSTEM; METABOLISM; NONHUMAN; OSTEOARTHRITIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84874538374     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-404717-4.00002-0     Document Type: Chapter

References (155)

1. Aderka D., Wysenbeek A., Engelmann H., Cope A.P., Brennan F., Molad Y., et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 1993, 36:1111-1120.
2. Albring J.C., Sandau M.M., Rapaport A.S., Edelson B.T., Satpathy A., Mashayekhi M., et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. Journal of Experimental Medicine 2010, 207:2551-2559.
3. Alcais A., Alter A., Antoni G., Orlova M., Nguyen V.T., Singh M., et al. Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy. Nature Genetics 2007, 39:517-522.
4. Alwawi E.A., Krulig E., Gordon K.B. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. Dermatology and Therapy 2009, 22:431-440.
5. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics 2011, 43:246-252.
6. Angel K., Provan S.A., Fagerhol M.K., Mowinckel P., Kvien T.K., Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. American Journal of Hypertension 2012, 25:644-650.
7. Atzeni F., Doria A., Carrabba M., Turiel M., Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmunity Reviews 2007, 6:529-536.
8. Balding J., Kane D., Livingstone W., Mynett-Johnson L., Bresnihan B., Smith O., et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis and Rheumatism 2003, 48:1408-1413.
9. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
10. Bassols J., Moreno J.M., Ortega F., Ricart W., Fernandez-Real J.M. Characterization of herpes virus entry mediator as a factor linked to obesity. Obesity (Silver Spring) 2010, 18:239-246.
11. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000, 343:1586-1593.
12. Beckham J.C., Caldwell D.S., Peterson B.L., Pippen A.M., Currie M.S., Keefe F.J., et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. Journal of Clinical Immunology 1992, 12:353-361.
13. Benitah N.R., Sobrin L., Papaliodis G.N. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Seminars in Ophthalmology 2011, 26:295-303.
14. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. American Journal of Gastroenterology 2011, 106:674-684.
15. Bodmer J.L., Schneider P., Tschopp J. The molecular architecture of the TNF superfamily. Trends in Biochemical Sciences 2002, 27:19-26.
16. Body J.J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical Cancer Research 2006, 12:1221-1228.
17. Bolstad A.I., Le Hellard S., Kristjansdottir G., Vasaitis L., Kvarnstrom M., Sjowall C., et al. Association between genetic variants in the tumour necrosis factor/lymphotoxin alpha/lymphotoxin beta locus and primary Sjogren's syndrome in Scandinavian samples. Annals of the Rheumatic Diseases 2012, 71:981-988.
18. Bossen C., Ingold K., Tardivel A., Bodmer J.L., Gaide O., Hertig S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. Journal of Biological Chemistry 2006, 281:13964-13971.
19. Bourne T., Fossati G., Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008, 22:331-337.
20. Boyce E.G., Halilovic J., Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clinical Therapeutics 2010, 32:1681-1703.
21. Brik R., Gepstein V., Shahar E., Goldsher D., Berkovitz D. Tumor necrosis factor blockade in the management of children with orphan diseases. Clinical Rheumatology 2007, 26:1783-1785.
22. Browning J.L., Ngam-ek A., Lawton P., DeMarinis J., Tizard R., Chow E.P., et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993, 72:847-856.
23. Browning J.L. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunological Reviews 2008, 223:202-220.
24. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., Cerami A. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:1670-1674.
25. Chen Y.F., Jobanputra P., Barton P., Jowett S., Bryan S., Clark W., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006, 10. iii-iv, xi-xiii, 1-229.
26. Chen C., Constantinou A., Deonarain M. Modulating antibody pharmacokinetics using hydrophilic polymers. Expert Opinion on Drug Delivery 2011, 8:1221-1236.
27. Cheung K.J., Johnson N.A., Affleck J.G., Severson T., Steidl C., Ben-Neriah S., et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Research 2010, 70:9166-9174.
28. Cheung T.C., Coppieters K., Sanjo H., Oborne L.M., Norris P.S., Coddington A., et al. Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability. Journal of Immunology 2010, 185:1949-1958.
29. Chiang E.Y., Kolumam G.A., Yu X., Francesco M., Ivelja S., Peng I., et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nature Medicine 2009, 15:766-773.
30. Chiang E.Y., Kolumam G., McCutcheon K.M., Young J., Lin Z., Balazs M., et al. In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease. PLoS ONE 2012, 7:e33106.
31. Christenson E.S., Jiang X., Kagan R., Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecologica 2012, 64:181-194.
32. Clarke R., Xu P., Bennett D., Lewington S., Zondervan K., Parish S., et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genetics 2006, 2:e107.
33. Coenen M.J., Trynka G., Heskamp S., Franke B., van Diemen C.C., Smolonska J., et al. Common and different genetic background for rheumatoid arthritis and coeliac disease. Human Molecular Genetics 2009, 18:4195-4203.
34. Cohavy O., Zhou J., Ware C.F., Targan S.R. LIGHT is constitutively Expressed on T and NK cells in the human gut and can Be induced by CD2-mediated signaling. Journal of Immunology 2005, 174:646-653.
35. Colombel J.F., Feagan B.G., Sandborn W.J., Van Assche G., Robinson A.M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflammatory Bowel Diseases 2012, 18:349-358.
36. Crowe P.D., VanArsdale T.L., Walter B.N., Ware C.F., Hession C., Ehrenfels B., et al. A lymphotoxin-beta-specific receptor. Science 1994, 264:707-710.
37. Crowe P.D., Walter B.N., Mohler K.M., Otten-Evans C., Black R.A., Ware C.F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. Journal of Experimental Medicine 1995, 181:1205-1210.
38. Cui J., Saevarsdottir S., Thomson B., Padyukov L., van der Helm-van Mil A.H., Nititham J., et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis and Rheumatism 2010, 62:1849-1861.
39. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. European Journal of Haematology 1995, 54:1-8.
40. Dinarello C.A. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. Journal of Rheumatology Supplement 2005, 74:40-47.
41. Doherty T.A., Soroosh P., Khorram N., Fukuyama S., Rosenthal P., Cho J.Y., et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nature Medicine 2011, 17:596-603.
42. Dubois P.C., Trynka G., Franke L., Hunt K.A., Romanos J., Curtotti A., et al. Multiple common variants for celiac disease influencing immune gene expression. Nature Genetics 2010, 42:295-302.
43. Edwards C.K. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Annals of the Rheumatic Diseases 1999, 58(Suppl. 1):I73-I81.
44. Ehlers S., Holscher C., Scheu S., Tertilt C., Hehlgans T., Suwinski J., et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. Journal of Immunology 2003, 170:5210-5218.
45. Emu B., Luca D., Offutt C., Grogan J.L., Rojkovich B., Williams M.B., et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin alpha: results of a phase I randomized, placebo-controlled trial. Arthritis Research and Therapy 2012, 14:R6.
46. Fallahi-Sichani M., Flynn J.L., Linderman J.J., Kirschner D.E. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. Journal of Immunology 2012, 188:3169-3178.
47. Favorova O.O., Favorov A.V., Boiko A.N., Andreewski T.V., Sudomoina M.A., Alekseenkov A.D., et al. Three allele combinations associated with multiple sclerosis. BMC Medical Genetics 2006, 7:63.
48. Feldmann M., Maini R.N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. Journal of Immunology 2010, 185:791-794.
49. Fernando M.M., Stevens C.R., Walsh E.C., De Jager P.L., Goyette P., Plenge R.M., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genetics 2008, 4:e1000024.
50. Fisher C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. New England Journal of Medicine 1996, 334:1697-1702.
51. Fleischmann R. The efficacy and safety of golimumab in the treatment of arthritis. Expert Opinion on Biological Therapy 2010, 10:1131-1143.
52. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Current Opinion in Rheumatology 2012, 24:335-341.
53. Folseraas T., Melum E., Rausch P., Juran B.D., Ellinghaus E., Shiryaev A., et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. Journal of Hepatology 2012, 57:366-375.
54. Fong K.Y., Boey M.L., Koh W.H., Feng P.H. Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions. Clinical and Experimental Rheumatology 1994, 12:55-58.
55. Freour T., Jarry A., Bach-Ngohou K., Dejoie T., Bou-Hanna C., Denis M.G., et al. TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. International Journal of Molecular Medicine 2009, 23:41-48.
56. Fu Z., Li D., Jiang W., Wang L., Zhang J., Xu F., et al. Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province. Breast Cancer Research and Treatment 2010, 120:195-202.
57. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2011, 63:3918-3930.
58. Furrer E., Berdugo M., Stella C., Behar-Cohen F., Gurny R., Feige U., et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Investigative Ophthalmology and Visual Science 2009, 50:771-778.
59. Furrer E., Hulmann V., Urech D.M. Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. Journal of Neuroimmunology 2009, 215:65-72.
60. Gatumu M.K., Skarstein K., Papandile A., Browning J.L., Fava R.A., Bolstad A.I. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Research and Therapy 2009, 11:R24.
61. Giardina E., Huffmeier U., Ravindran J., Behrens F., Lepre T., McHugh N.J., et al. Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis and Rheumatism 2011, 63:3801-3806.
62. Gregory A.P., Dendrou C.A., Attfield K.E., Haghikia A., Xifara D.K., Butter F., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511.
63. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Seminars in Arthritis and Rheumatism 2005, 34:7-11.
64. Horiuchi T., Mitoma H., Harashima S., Tsukamoto H., Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010, 49:1215-1228.
65. Hornig N., Farber-Schwarz A. Production of bispecific antibodies: diabodies and tandem scFv. Methods in Molecular Biology 2012, 907:713-727.
66. Hughes L.B., Criswell L.A., Beasley T.M., Edberg J.C., Kimberly R.P., Moreland L.W., et al. Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes and Immunity 2004, 5:641-647.
67. Kabat E.A. Antibody complementarity and antibody structure. Journal of Immunology 1988, 141:S25-S36.
68. Kay J., Rahman M.U. Golimumab: a novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evidence 2010, 4:159-170.
69. Kay J., Matteson E.L., Dasgupta B., Nash P., Durez P., Hall S., et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis and Rheumatism 2008, 58:964-975.
70. Kaymakcalan Z., Sakorafas P., Bose S., Scesney S., Xiong L., Hanzatian D.K., et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clinical Immunology 2009, 131:308-316.
71. Kerensky T.A., Gottlieb A.B., Yaniv S., Au S.C. Etanercept: efficacy and safety for approved indications. Expert Opinion on Drug Safety 2012, 11:121-139.
72. Keystone E., Heijde D., Mason D., Landewe R., Vollenhoven R.V., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism 2008, 58:3319-3329.
73. Keystone E.C. The utility of tumour necrosis factor blockade in orphan diseases. Annals of the Rheumatic Diseases 2004, 63(Suppl. 2):ii79-ii83.
74. Keyszer G., Lambiri I., Nagel R., Keysser C., Keysser M., Gromnica-Ihle E., et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. Journal of Rheumatology 1999, 26:251-258.
75. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731-740.
76. Kishore U., Gaboriaud C., Waters P., Shrive A.K., Greenhough T.J., Reid K.B., et al. C1q and tumor necrosis factor superfamily: modularity and versatility. Trends in Immunology 2004, 25:551-561.
77. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU- rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
78. Kurreeman F.A., Stahl E.A., Okada Y., Liao K., Diogo D., Raychaudhuri S., et al. Use of a multiethnic approach to identify rheumatoid- arthritis-susceptibility loci, 1p.36 and 17q12. American Journal of Human Genetics 2012, 90:524-532.
79. Laws S.M., Perneczky R., Wagenpfeil S., Muller U., Forstl H., Martins R.N., et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Human Mutation 2005, 26:29-35.
80. Li J., Hsu H.C., Mountz J.D. Managing macrophages in rheumatoid arthritis by reform or removal. Current Rheumatology Reports 2012, 14:445-454.
81. Lichtenstein G.R., Yan S., Bala M., Blank M., Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
82. Lichtenstein G.R., Thomsen O.O., Schreiber S., Lawrance I.C., Hanauer S.B., Bloomfield R., et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clinical Gastroenterology and Hepatology 2010, 8:600-609.
83. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001, 104:487-501.
84. Maneiro J.R., Salgado E., Gomez-Reino J.J., Carmona L. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish Registry of biologics BIOBADASER and a systematic review. Seminars in Arthritis and Rheumatism 2012, 42:89-103.
85. Martyn-Simmons C.L., Green L., Ash G., Groves R.W., Smith C.H., Barker J.N. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. Journal of the European Academy of Dermatology and Venereology 2009, 23:1394-1397.
86. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8:21-30.
87. McGovern J.L., Nguyen D.X., Notley C.A., Mauri C., Isenberg D.A., Ehrenstein M.R. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis and Rheumatism 2012, 64:3129-3138.
88. Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Therapeutics and Clinical Risk Management 2006, 2:389-400.
89. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009, 84:14-24.
90. Moots R.J., Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012, 51:2252-2261.
91. Murdaca G., Colombo B.M., Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barcelona) 2011, 47:277-288.
92. Murphy T.L., Murphy K.M. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annual Review of Immunology 2010, 28:389-411.
93. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. Journal of Experimental Medicine 2007, 204:33-39.
94. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nature Genetics 2009, 41:199-204.
95. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
96. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflammatory Bowel Diseases 2007, 13:1323-1332.
97. O'Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7113-7118.
98. Ottiger M., Thiel M.A., Feige U., Lichtlen P., Urech D.M. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Investigative Ophthalmology and Visual Science 2009, 50:779-786.
99. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., Ippoliti A., Dubinsky M.C., Birt J., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. American Journal of Gastroenterology 2005, 100:75-79.
100. Papp K. Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. Current Medical Research and Opinion 2010, 26:2287-2300.
101. Pasero C., Truneh A., Olive D. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting. Current Molecular Medicine 2009, 9:911-927.
102. Peddi P., Lopez-Olivo M.A., Pratt G.F., Suarez-Almazor M.E. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treatment Reviews 2013, 39:97-104.
103. Pinckard J.K., Sheehan K.C.F., Arthur C.D., Schreiber R.D. Constitutive shedding of both p.55 and p.75 murine TNF receptors in vivo. Journal of Immunology 1997, 158:3869-3873.
104. Pineda G., Ea C.K., Chen Z.J. Ubiquitination and TRAF signaling. Advances in Experimental Medicine and Biology 2007, 597:80-92.
105. Prajapati R., Plant D., Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 2011, 12:1571-1585.
106. Quesniaux V.F., Jacobs M., Allie N., Grivennikov S., Nedospasov S.A., Garcia I., et al. TNF in host resistance to tuberculosis infection. Current Directions in Autoimmunity 2010, 11:157-179.
107. Radouane A., Oudghiri M., Chakib A., Bennani S., Touitou I., Barat-Houari M. SNPs in the TNF-alpha gene promoter associated with Behcet's disease in Moroccan patients. Rheumatology (Oxford) 2012, 51:1595-1599.
108. Rajaram M.V., Ni B., Morris J.D., Brooks M.N., Carlson T.K., Bakthavachalu B., et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:17408-17413.
109. Ramos-Casals M., Brito-Zeron P., Munoz S., Soto M.J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008, 87:345-364.
110. Ritchlin C.T. Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists. Best Practice and Research Clinical Rheumatology 2010, 24:683-692.
111. Roach D.R., Briscoe H., Saunders B., France M.P., Riminton S., Britton W.J. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. Journal of Experimental Medicine 2001, 193:239-246.
112. Rooney M., David J., Symons J., Di Giovine F., Varsani H., Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. British Journal of Rheumatology 1995, 34:454-460.
113. Saftig P., Reiss K. The "A Disintegrin and Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?. European Journal of Cell Biology 2011, 90:527-535.
114. Sandborn W.J., Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122:1592-1608.
115. Sandborn W.J. State-of-the-art: Immunosuppression and biologic therapy. Digestive Diseases 2010, 28:536-542.
116. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
117. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
118. Scheller J., Chalaris A., Garbers C., Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends in Immunology 2011, 32:380-387.
119. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. Journal of Experimental Medicine 1998, 187:1205-1213.
120. Schrofelbauer B., Hoffmann A. How do pleiotropic kinase hubs mediate specific signaling by TNFR superfamily members?. Immunological Reviews 2011, 244:29-43.
121. Sedy J.R., Spear P.G., Ware C.F. Cross-regulation between herpesviruses and the TNF superfamily members. Nature Reviews Immunology 2008, 8:861-873.
122. Seko Y., Cole S., Kasprzak W., Shapiro B.A., Ragheb J.A. The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmunity Reviews 2006, 5:299-305.
123. Selby P., Hobbs S., Viner C., Jackson E., Jones A., Newell D., et al. Tumour necrosis factor in man: clinical and biological observations. British Journal of Cancer 1987, 56:803-808.
124. Shaikh R.B., Santee S., Granger S.W., Butrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. Journal of Immunology 2001, 167:6330-6337.
125. Shaw G., Kamen R. A conserved AU sequence from the 3' untranslated region of GM- CSF mRNA mediates selective mRNA degradation. Cell 1986, 46:659-667.
126. Shealy D., Cai A., Staquet K., Baker A., Lacy E.R., Johns L., et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010, 2.
127. Simpson P.D., Moysi E., Wicks K., Sudan K., Rowland-Jones S.L., McMichael A.J., et al. Functional differences exist between TNFalpha promoters encoding the common -237G SNP and the rarer HLA-B*5701-linked a variant. PLoS ONE 2012, 7:e40100.
128. Sinha S., Mishra S.K., Sharma S., Patibandla P.K., Mallick P.K., Sharma S.K., et al. Polymorphisms of TNF-enhancer and gene for FcgammaRIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population. Malaria Journal 2008, 7:13.
129. Solomon A.J., Spain R.I., Kruer M.C., Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Multiple Sclerosis 2011, 17:1472-1487.
130. Soroosh P., Doherty T.A., So T., Mehta A.K., Khorram N., Norris P.S., et al. Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. Journal of Experimental Medicine 2011, 208:797-809.
131. Spencer S., Marini B.L., Figg W.D. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Research 2012, 32:2391-2398.
132. Spies T., Morton C.C., Nedospasov S.A., Fiers W., Pious D., Strominger J.L. Genes for the tumor necrosis factors a and b are linked to the human major histocompatibility complex. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:8699-8702.
133. Steinberg M.W., Cheung T.C., Ware C.F. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunological Reviews 2011, 244:169-187.
134. Stohl W., Hilbert D.M. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nature Biotechnology 2012, 30:69-77.
135. Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744.
136. Tabrizi M.A., Tseng C.M., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today 2006, 11:81-88.
137. Talley N.J., Abreu M.T., Achkar J.P., Bernstein C.N., Dubinsky M.C., Hanauer S.B., et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. American Journal of Gastroenterology 2011, 106(Suppl. 1):S2-S25. quiz S26.
138. Tang R., Sinnwell J.P., Li J., Rider D.N., de Andrade M., Biernacka J.M. Identification of genes and haplotypes that predict rheumatoid arthritis using random forests. BMC Proceedings 2009, 3(Suppl. 7):S68.
139. Tello-Ruiz M.K., Curley C., DelMonte T., Giallourakis C., Kirby A., Miller K., et al. Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19. European Journal of Human Genetics 2006, 14:780-790.
140. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. Journal of Immunology 2007, 179:5082-5089.
141. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology and Therapeutics 2008, 117:244-279.
142. Treml J.F., Hao Y., Stadanlick J.E., Cancro M.P. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochemistry and Biophysics 2009, 53:1-16.
143. Urech D.M., Feige U., Ewert S., Schlosser V., Ottiger M., Polzer K., et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use. Annals of the Rheumatic Diseases 2010, 69:443-449.
144. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
145. Vasilopoulos Y., Manolika M., Zafiriou E., Sarafidou T., Bagiatis V., Kruger-Krasagaki S., et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Molecular Diagnosis and Therapy 2012, 16:29-34.
146. Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunological Reviews 2011, 244:9-28.
147. Wallis R.S. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infectious Disease Clinics of North America 2011, 25:895-910.
148. Wang X., Cheng S., Brophy V.H., Erlich H.A., Mannhalter C., Berger K., et al. A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke 2009, 40:683-695.
149. Ware C.F., Sedy J.R. TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14). Current Opinion in Immunology 2011, 23:627-631.
150. Ware C.F. Network communications: lymphotoxins, light, and TNF. Annual Review of Immunology 2005, 23:787-819.
151. Ware C.F. Targeting the LIGHT-HVEM pathway. Advances in Experimental Medicine and Biology 2009, 647:146-155.
152. Wiens G.D., Glenney G.W. Origin and evolution of TNF and TNF receptor superfamilies. Developmental and Comparative Immunology 2011, 35:1324-1335.
153. Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. Journal of Experimental Medicine 2004, 200:367-376.
154. Yang T., Wang Z., Wu F., Tan J., Shen Y., Li E., et al. A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis. PLoS Computational Biology 2010, 6:e1000669.
155. Zhang J., Xie F., Delzell E., Chen L., Winthrop K.L., Lewis J.D., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012, 308:43-49.